Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melinta Therapeutics Inc.

www.melinta.com

Latest From Melinta Therapeutics Inc.

The Medicines Co. Names Mark Timney As CEO In A Shakeup

CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.

Leadership Business Strategies

Outcomes-Based Contracts May Be Negotiated By Michigan Medicaid

Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.

Pricing Strategies Reimbursement

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies

Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Rib-X Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Melinta Therapeutics Inc.
  • Senior Management
  • Dan Wechsler, Pres. & CEO
    Paul Estrem, CFO
    Sue Cammarata, MD, CMO
    Lyn Baranowski, SVP, Corp. Dev. & Strategy
    Erin Duffy, PhD, CSO
    John Temperato, Chief Commercial Officer
  • Contact Info
  • Melinta Therapeutics Inc.
    Phone: (203) 624-5606
    300 George St., Ste. 301
    New Haven, CT 06511-6663
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register